BioCryst hopes to raise $57.8M in stock offering to fund R&D efforts

11/18/2009 | American City Business Journals

BioCryst Pharmaceuticals plans to sell 5 million shares of stock in order to secure $57.8 million. The biotech company will use the money from the stock offering to fund clinical studies of lymphoma treatment Forodesine and BCX-4208, a gout drug, as well as support premarketing efforts for Forodesine and flu drug Peramivir.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC